In an effort to get to the root of healthcare spending in the United States, the National Pharmaceutical Council launched the Going Below the Surface initiative.
In an effort to get to the root of healthcare spending in the United States, the National Pharmaceutical Council launched the Going Below the Surface initiative. In addition to examining the drivers of healthcare spending, the initiative is creating a national multistakeholder dialogue to determine best practices for optimizing spending.
Today, we speak with Bobby Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council, about the initiative, its goals, and what it has found so far.
To listen to the podcast, please login.
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Listen above or or through one of these podcast services:
Learn more about drug prices in the United States and efforts to lower them:
From Patient Advocates to Pharma, Groups Weigh in on Trump Blueprint for Drug Costs
Healthcare Spending Driven by Price, Not Utilization: JAMA Study
A Look at the Legal and Legislative Landscape Impacting Drug Costs for Patients
October 23rd 2024Kimberly Westrich, MA, of National Pharmaceutical Council, and Adam Colborn, JD, of AMCP, run through the current status of lawsuits and lawmaking at the federal and state levels related to pharmacy benefit managers and cost-shifting programs.
Read More
Dr John M. O'Brien Highlights Critical Role of Rebates in Employer Benefit Choices
August 5th 2024John M. O'Brien, PharmD, MPH, of the National Pharmaceutical Council, discusses his recent study, which sheds light on how important rebates are when choosing benefits for employers and who advises employers on these choices.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More